Antiretroviral therapy

Antiretroviral therapy has been studied in 228 papers since 2010: 2 trials and 137 observational studies in people, 2 in animals, 84 reviews; 69 in the past year. The newest paper, Nov 11, 2026: “Prevalence and Factors Associated with Erectile Dysfunction Among Men Living with HIV: A Systematic Review, Meta-Analysis, and Meta-Regression”.

Intervention

228 papers study it148 findingsUpdated

Research on it is growing 10% faster than aging research as a whole: 54 papers in the latest year counted

10 new papers in 30 daysSee all 226 papers on antiretroviral therapy

At a glance

Independent labs found the same change in people. 54 independent labs in 27 countries.

“Markers of CD4(+) T-cell senescence (ie, the percentage of CD28(-)CD57(+) cells among CD4(+) T cells ) and CD4(+)/CD8(+) T-cell exhaustion (ie, the percentage of PD-1(+) cells among CD4(+)/CD8(+) T cells) decreased after ART.”
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260sThe Journal of infectious diseases2016doi:10.1093/infdis/jiw253

7 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 54 independent labs in 27 countries
  • 7 findings against
  • Funders: National Institutes of Health and others
  • 8 of 92 findings with company ties
  • Human trial2
  • Humans136
  • Animals2
  • In silico1

Studies in people

2 studies gave antiretroviral therapy to people and measured what changed.

What changedDesignPeopleSource

down: Decreases epigenetic age

Randomized trial2 years168 peopleIn ART-naive adults with HIV, before versus after ART initiationThe lancet. HIV, Apr 1, 2021

down: Decreases PD-1+ T cells

no change: Has no effect on CD8+ T-cell senescence markers

Randomized trial96-week328 peoplePatient cohortsThe Journal of infectious diseases, Jun 28, 2016

What did studies of antiretroviral therapy find?

53

Studies of antiretroviral therapy measured 53 outcomes; the most studied are lifespan (24 studies), cellular senescence (5) and life expectancy (4).

Lifespan

upin humans24

24 studies
  1. Antiretroviral therapy extends lifespan in humans (people living with HIV).

    “Although antiretroviral therapy (ART) has extended the lifespan of people living with HIV (PWH), many experience complex age-related comorbidities and functional decline.”

    Reviewpeople living with HIV

    Exercise to Mitigate the Effects of Aging With HIV: A Narrative Review With Exercise Recommendations for Practice

    The Journal of the Association of Nurses in AIDS Care : JANAC

  2. Antiretroviral therapy extends lifespan in humans.

    “This ART paradox reflects the unintended consequence of extending WLHIV lifespan into cancer-vulnerable age cohorts”

    Reviewfemales

    Cervical Cancer Screening in Women Living with HIV in South Africa: Addressing Health Disparities Through Integrated Prevention Strategies

    International journal of women's health

  3. Antiretroviral therapy extends lifespan in people living with HIV.

    “Advances in antiretroviral therapy (ART) have extended the life expectancy of people living with HIV (PWH) in Peru”

    Reviewin people living with HIV

    A Review of Chronic Comorbidities in People Living With HIV in Peru

    Journal of the International Association of Providers of AIDS Care

  4. Antiretroviral therapy extends lifespan in people living with HIV.

    “Antiretroviral therapy has extended the lifespan of HIV/ADIS.”

    Reviewin people living with HIV

    Longitudinal trends in HIV/AIDS adults aged over 60 years: A multidimensional decomposition with global and regional comparisons, 1990-2021

    Journal of infection and public health

  5. Antiretroviral therapy extends lifespan in humans.

    “With the extensive implementation of antiretroviral therapy (ART), the life expectancy of people living with HIV (PLWH) has markedly extended.”

    Review

    HIV infection, antiretroviral therapy and vascular dysfunction: Effects, mechanisms and treatments

    Pharmacological research

  6. Antiretroviral therapy extends lifespan in persons with HIV in the United States.

    “average lifespans of persons with HIV (PWH) in the United States have increased significantly in recent decades”

    Reviewin persons with HIV in the United States

    Aging and mortality of persons with HIV: a novel Kalman Filtering and DMD framework

    arXiv (Cornell University)Preprint

  7. Antiretroviral therapy extends lifespan in people living with HIV.

    “The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV.”

    Reviewin people living with HIV

    Prevention and control of HPV-related cancers in people living with HIV

    The lancet. HIV

  8. Antiretroviral therapy extends lifespan in people living with HIV.

    “The increasing lifespan of people living with HIV (PLWH) due to advancements in antiretroviral therapy (ART)”

    Reviewin people living with HIV

    A Comprehensive Review of the Manifestation of Cardiovascular Diseases in HIV Patients

    Cureus

  9. Antiretroviral therapy extends lifespan in humans (HIV).

    “antiretroviral therapy (ART) has resulted in significant improvement in life expectancy for people with HIV.”

    ReviewHIV

    Challenges of HIV Management in an Aging Population

    Current HIV/AIDS reports

  10. Antiretroviral therapy extends lifespan in humans (HIV care) (dramatically extended).

    “Integrating antiretroviral therapy into HIV care dramatically extended the lifespan for people living with HIV.”

    ReviewHIV care

    Current Challenges, Solutions, and Novel Directions in Research and Clinical Care: Proceedings From the 14th Annual International Workshop on HIV and Aging

    The journals of gerontology. Series A, Biological sciences and medical sciences

All 24

Cellular senescence

upin humans2no changein humans2downin humans1

5 studies
  1. Antiretroviral therapy showed no clear effect on cellular senescence in acute HIV infection.

    “which were not normalized by early ART.”

    Human trialin acute HIV infectionPBMC

    FoxP3⁺ CD8 T-cells in acute HIV infection and following early antiretroviral therapy initiation

    Frontiers in immunology

  2. Antiretroviral therapy is linked with cellular senescence in humans.

    “We showed that continuous ART induces a progressive senescence-like pro-inflammatory state in AM characterized by increased constitutive epigenetic and transcriptomic priming of genes involved in cell-cycle arrest and senescence.”

    Humansalveolar macrophages

    Continuous antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages

    Frontiers in immunology

  3. Antiretroviral therapy was not clearly linked with cellular senescence in humans (chronic and advanced HIV infection, one year on ART).

    “which generally persisted after ART, but not in PWH treated in primary HIV infection”

    Humanschronic and advanced HIV infection, one year on ARTT cell, monocyteone yearmalesn = 39

    Changes in Cellular Senescence Biomarkers Across Individuals at Different Stages of HIV Infection Before and After a Year on Antiretroviral Therapy

    The Journal of infectious diseases

  4. Antiretroviral therapy is linked with lower cellular senescence in humans (compared to late-suppressed and not-suppressed PHIVAYA).

    “ES-PHIVAYA exhibited significantly lower HIV-DNA reservoir, decreased percentages of senescent and exhausted CD4 and CD8 T cells”

    Humanscompared to late-suppressed and not-suppressed PHIVAYAbloodn = 6

    HIV reservoir and premature aging: risk factors for aging-associated illnesses in adolescents and young adults with perinatally acquired HIV

    PLoS pathogens

  5. Antiretroviral therapy induces cellular senescence in humans.

    “HIV patients experience several stressors such as the virus itself, antiretroviral drugs and to a lesser extent, substance abuse that can induce cellular senescence.”

    Review

    HIV-associated cellular senescence: A contributor to accelerated aging

    Ageing research reviews

More on Cellular senescence

Life expectancy

upin humans4

4 studies
  1. Antiretroviral therapy improves life expectancy in humans.

    “Antiretroviral therapy has extended the life expectancy of people with HIV (PWH)”

    Review

    HIV infection and immunosenescence: challenges and intervention strategies

    BMC medicine

  2. Antiretroviral therapy improves life expectancy in humans (people living with HIV).

    “The advent of antiretroviral therapy has markedly improved the life expectancy of individuals with HIV”

    Reviewpeople living with HIV

    Atherosclerosis and HIV: Exploring Cardiovascular Risks and Management

    Cardiology in review

  3. Antiretroviral therapy improves life expectancy in people with HIV.

    “The drastic improvement in life expectancy of people with HIV has led to an expansion of the aging population of people with HIV globally.”

    Reviewin people with HIV

    Neurocognition and the Aging Brain in People With HIV: Implications for Screening

    Topics in antiviral medicine

  4. Antiretroviral therapy increases life expectancy in humans (people living with HIV).

    “With the introduction of effective antiretroviral therapy, the life expectancy of people living with HIV has improved.”

    Reviewpeople living with HIV

    Ageing in patients with chronic HIV infection: impact of hypercoagulation

    AIDS research and therapy

Epigenetic age

downin humans3

3 studies
  1. Antiretroviral therapy decreases epigenetic age in ART-naive adults with HIV, before versus after ART initiation.

    “After 2 years of ART, epigenetic age acceleration was reduced”

    Human trialin ART-naive adults with HIV, before versus after ART initiationwhole blood2 yearsn = 168

    Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial

    The lancet. HIV

  2. Antiretroviral therapy is linked with lower epigenetic age in humans (people living with HIV).

    “ART therapy mitigated the advancement of DNA methylation age.”

    Humanspeople living with HIV

    Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIV

    Cancer medicine

  3. Antiretroviral therapy decreases epigenetic age in people with HIV.

    “Epigenetic age acceleration (EAA) in PWH has now clearly been shown to be potentially reversible during successful antiretroviral therapy (ART).”

    Reviewin people with HIV

    Perspective: clinical relevance of epigenetic aging and HIV

    Epigenomics

More on Epigenetic age

Mortality

downin humans3

3 studies
  1. Antiretroviral therapy decreases mortality in humans (living with HIV).

    “Antiretroviral therapy (ART) has significantly improved mortality rates for individuals living with HIV”

    Reviewliving with HIV

    Burden of Kidney Disease in an Aging Population Living with HIV in the United States

    AIDS patient care and STDs

  2. Antiretroviral therapy decreases mortality in HIV-infected people.

    “The mortality rate associated with HIV infection plummeted after the introduction of effective antiretroviral therapy pioneered two decades ago.”

    Reviewin HIV-infected people

    Understanding mechanisms to promote successful aging in persons living with HIV

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

  3. Antiretroviral therapy decreases mortality in humans (HIV infection).

    “Although introduction of antiretroviral therapy (ART) has led to significant reduction in morbidity and mortality of HIV-infected patients, viral replication persists.”

    ReviewHIV infection

    HIV Infection and Compromised Mucosal Immunity: Oral Manifestations and Systemic Inflammation

    Frontiers in immunology

PhenoAge

no changein humans2

2 studies
  1. Antiretroviral therapy was not clearly linked with PhenoAge in humans (virally suppressed on ART) (-0.38 vs -0.47 years).

    “the median PAA values at T0 and T5 were -0.38 and -0.47 years, indicating non-significant change over five years”

    Humansvirally suppressed on ART5 yearsn = 728

    Stability and Predictors of Phenotypic Age Acceleration among Virally Suppressed Asians with HIV over Five Years

    The journals of gerontology. Series A, Biological sciences and medical sciences

  2. Antiretroviral therapy was not clearly linked with PhenoAge in humans (long-term aviremic HIV-infected adults on stable ART).

    “After 4 years of follow-up, PhenoAge-EAA and GrimAge-EAA showed no differences”

    Humanslong-term aviremic HIV-infected adults on stable ART4 yearsn = 63

    Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus-Infected Recipients of Long-term Antiretroviral Treatment

    The Journal of infectious diseases

More on PhenoAge

Inflammation

downin humans1upin humans1

2 studies
  1. Antiretroviral therapy is linked with inflammation in humans.

    “We showed that continuous ART induces a progressive senescence-like pro-inflammatory state in AM”

    Humansalveolar macrophages

    Continuous antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages

    Frontiers in immunology

  2. Antiretroviral therapy decreases inflammation in HIV-infected microglia.

    “ART mitigates these effects but does not fully restore to levels observed in HIV-uninfected conditions.”

    Reviewin HIV-infected microgliabrain

    Implications of HIV persistence and pathogenesis in microglia

    Current opinion in HIV and AIDS

More on Inflammation

Biological age

downin humans2

2 studies
  1. Antiretroviral therapy is linked with lower biological age in people with HIV.

    “specific antiretroviral drugs reduce age acceleration”

    Humansin people with HIV

    Opposite effects of chronic HIV infection and antiretroviral medication on organismal and organ-specific biological aging

    Nature communications

  2. Antiretroviral therapy decreases biological age in people living with HIV.

    “The ART initiation reverses the biological ageing process but only partially”

    Reviewin people living with HIV

    Ageing with HIV: Challenges and biomarkers

    EBioMedicine

Horvath clock

downin humans2

2 studies
  1. Antiretroviral therapy is linked with lower Horvath clock in humans (people with HIV on suppressive ART) (-0.35 years/year (95% CI -0.44 to -0.27)).

    “Per year of suppressive ART (median observation 9·8 years, IQR 7·2-11), mean EAA was -0·35 years (95% CI -0·44 to -0·27) for Horvath's clock”

    Humanspeople with HIV on suppressive ARTperipheral blood mononuclear cellsmedian observation 9.8 years (IQR 7.2-11)n = 80

    Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years

    The lancet. Healthy longevity

  2. Antiretroviral therapy is linked with lower Horvath clock in humans (long-term aviremic HIV-infected adults on stable ART) (median difference, -0.53 years, P = .015).

    “whereas Horvath-EAA slightly decreased (median difference, -0.53 years; P = .015).”

    Humanslong-term aviremic HIV-infected adults on stable ART4 yearsn = 63

    Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus-Infected Recipients of Long-term Antiretroviral Treatment

    The Journal of infectious diseases

More on Horvath clock

p16INK4a

no changein humans1downin humans1

1 study
  1. Antiretroviral therapy was not clearly linked with p16INK4a in humans (chronically HIV-infected patients).

    “ART restored p16 protein expression to levels comparable with HIV-negative subjects in the CD4 compartment, but not in CD8 T cells”

    Humanschronically HIV-infected patientsCD8 T cells

    p16INK4a Expression and Immunologic Aging in Chronic HIV Infection

    PloS one

  2. Antiretroviral therapy is linked with lower p16INK4a in humans (chronically HIV-infected patients).

    “ART restored p16 protein expression to levels comparable with HIV-negative subjects in the CD4 compartment”

    Humanschronically HIV-infected patientsCD4 T cells

    p16INK4a Expression and Immunologic Aging in Chronic HIV Infection

    PloS one

More on p16INK4a

KLRG1

upin humans1

1 study
  1. Antiretroviral therapy increases KLRG1 in PWH during the first 4 y of ART.

    “accompanied an overall increase in NK surface expression of CD57 and KLRG1, suggestive of progression toward immune senescence.”

    Human trialin PWH during the first 4 y of ART4 yn = 60

    Persistence of a Skewed Repertoire of NK Cells in People with HIV-1 on Long-Term Antiretroviral Therapy

    Journal of immunology (Baltimore, Md. : 1950)

More on KLRG1

CD57

upin humans1

1 study
  1. Antiretroviral therapy increases CD57 in PWH during the first 4 y of ART.

    “Throughout this regimen, a skewed repertoire of cytokine unresponsive FcRγ- memory-like NK cells persisted and accompanied an overall increase in NK surface expression of CD57 and KLRG1”

    Human trialin PWH during the first 4 y of ART4 yn = 60

    Persistence of a Skewed Repertoire of NK Cells in People with HIV-1 on Long-Term Antiretroviral Therapy

    Journal of immunology (Baltimore, Md. : 1950)

More on CD57

FoxP3+ CD8 T-cells

downin humans1

1 study
  1. Antiretroviral therapy decreases FoxP3+ CD8 T-cells in acute HIV infection.

    “early ART normalized only the frequencies of total FoxP3+ CD8 T-cells.”

    Human trialin acute HIV infectionPBMCmedian 5.5 months post-infection

    FoxP3⁺ CD8 T-cells in acute HIV infection and following early antiretroviral therapy initiation

    Frontiers in immunology

More on FoxP3+ CD8 T-cells

Blood telomere length

upin humans1

1 study
  1. Antiretroviral therapy increases blood telomere length in humans after 96 weeks of first-line antiretroviral therapy in HIV-1-positive individuals (+0.04 T/S ratio).

    “we found after 96 weeks a statistically significant increase in blood telomere length (TL) of 0.04 (T/S Ratio) (p = 0.03)”

    Human trialafter 96 weeks of first-line antiretroviral therapy in HIV-1-positive individualsblood96 weeksn = 31

    Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals

    PloS one

More on Blood telomere length

CD127+ CD8+ T cells

upin humans1

1 study
  1. Antiretroviral therapy increases CD127+ CD8+ T cells in humans after initiation of ART.

    “The frequency of CD127+ CD8+ cells increased in Tcm and TemRO.”

    Human trialafter initiation of ART

    Partial recovery of senescence and differentiation disturbances in CD8⁺ T cell effector-memory cells in HIV-1 infection after initiation of anti-retroviral treatment

    Clinical and experimental immunology

More on CD127+ CD8+ T cells

All 53

What is antiretroviral therapy linked with?

46

Studies link antiretroviral therapy with 46 measures, most often frailty (4 studies), metabolic syndrome (2) and multimorbidity (2).

Frailty

upin humans3downin humans1

4 studies
  1. Antiretroviral therapy is linked with a higher risk of frailty in PLWH.

    “prolonged ARV exposure and polypharmacy significantly increase frailty risk.”

    Humansin PLWH

    Influence of antiretroviral therapy on frailty among people living with HIV

    Scientific reports

  2. Antiretroviral therapy is linked with a lower risk of frailty in humans (independent of age and years lived with HIV) (aOR 0.39, 95% CI 0.19-0.78).

    “each 5 years of ART use was associated with 60% lower odds of frailty/pre-frailty (aOR = 0.39, 95% CI: 0.19-0.78), independent of age and years lived with HIV.”

    Humansindependent of age and years lived with HIVeach 5 years of ART usen = 223

    Prevalence, factors and quality of life associated with frailty and pre-frailty in middle-aged and older adults living with HIV in Zimbabwe: A cross-sectional study

    HIV medicine

  3. Antiretroviral therapy is associated with frailty in humans (third-line regimen).

    “A CD4 count <200 cells/mm3, depression, low income, and use of third-line ART were variables significantly associated with a greater risk to present frail or prefrail status.”

    Humansthird-line regimenthird-linen = 231

    High Prevalence of Frailty and Prefrailty Status in Brazilian Patients Living with HIV

    AIDS research and human retroviruses

  4. Antiretroviral therapy raises the risk of frailty in humans (HIV).

    “driven by factors, like chronic inflammation, antiretroviral therapy toxicity, and traditional risk factors.”

    ReviewHIV

    A Perspective on Frailty and its Predisposing Factors among People Living with HIV

    Current HIV research

Metabolic syndrome

upin humans2OR 1.504

2 studies
  1. Antiretroviral therapy is associated with metabolic syndrome in PLHIV in SSA.

    “Longer ART duration, and in two Zambian studies, integrase inhibitor-based regimens (particularly dolutegravir) were associated with increased MetS risk”

    Reviewin PLHIV in SSA

    Cardiometabolic Disease in Aging HIV-Positive Populations in Sub-Saharan Africa: A Scoping Review of Long-Term Antiretroviral Therapy Effects

    Research SquarePreprint

  2. Antiretroviral therapy is associated with metabolic syndrome in humans (people living with HIV/AIDS; compared with no treatment) (pooled OR 1.504, 95% CI 1.217–1.859).

    “ART exposure had 1.5 times greater odds of having MetS than nontreatment had”

    Reviewpeople living with HIV/AIDS; compared with no treatment

    Burden of metabolic syndrome in the global adult HIV-infected population: a systematic review and meta-analysis

    BMC public health

More on Metabolic syndrome

Multimorbidity

downin humans1upin humans1

2 studies
  1. Antiretroviral therapy is associated with multimorbidity in people living with HIV.

    “Initiating ART within 31-90 days after diagnosis was associated with reduced odds of multimorbidity”

    Humansin people living with HIVwithin 31-90 days after diagnosis

    Multimorbidity Patterns and Cluster Characteristics Among People Living with HIV in the Korean HIV/AIDS Cohort, 2006-2023

    Public health weekly report

  2. Antiretroviral therapy is associated with multimorbidity in persons living with HIV (aRR 1.36, 95% CI 1.21-1.54).

    “multimorbidity (aRR 1.36, 95% CI 1.21-1.54)”

    Humansin persons living with HIV

    Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

    BMC infectious diseases

Telomere length

upin humans1mixedin humans1

2 studies
  1. Antiretroviral therapy is associated with telomere length in PLWH.

    “Initiation of antiretroviral therapy (ART) has been associated with partial recovery of TL”

    Reviewin PLWH

    Telomere length dynamics in adults living with HIV: A systematic review

    BMC infectious diseases

  2. Antiretroviral therapy is associated with telomere length in humans.

    “Some studies found no association between antiretroviral therapy (ART) and telomere length shortening, while others found an association between ART and telomere length shortening.”

    Review

    The Impact of HIV and Parasite Single Infection and Coinfection on Telomere Length: A Systematic Review

    Current issues in molecular biology

More on Telomere length

Atherosclerosis

downin humans1upin rhesus monkeys1

2 studies
  1. Antiretroviral therapy is associated with atherosclerosis in rhesus monkeys (chronic SIV infection).

    “Pathologic evaluation of a carotid artery from an SIV-infected, long-term ART-treated macaque revealed macrophage-rich plaques with p21+ senescent cells with intraluminal thrombus formation”

    Animalschronic SIV infectioncarotid arterylong-term

    Persistent activation of monocytes/macrophages and cell senescence in SIV-infected macaques on ART

    Frontiers in immunology

  2. Antiretroviral therapy lowers the risk of atherosclerosis in people living with HIV.

    “Although contemporary ART decreases this enhanced risk, it inherently increases the risk for abnormal lipid profile, MetS, weight gain, and obesity.”

    Reviewin people living with HIV

    The Impact of Contemporary Antiretroviral Drugs on Atherosclerosis and Its Complications in People Living With HIV: A Systematic Review

    Cureus

More on Atherosclerosis

Type 2 diabetes

upin humans2

2 studies
  1. Antiretroviral therapy raises the risk of type 2 diabetes in humans (people living with HIV on antiretroviral therapy).

    “Longer duration on ART, particularly > 5 or > 10 years, and specific ART regimens (e.g., those containing didanosine, stavudine, or PIs) were often associated with increased T2DM risk.”

    Reviewpeople living with HIV on antiretroviral therapy> 5 or > 10 years

    A systematic review assessing body mass index and waist circumference as predictors for the development of type 2 diabetes mellitus among people living with HIV on antiretroviral therapy

    BMC infectious diseases

  2. Antiretroviral therapy raises the risk of type 2 diabetes in older people living with HIV.

    “the risks associated with Type 2 DM among older PLWH were long duration of HIV infection; the use of older-generation antiretroviral therapy; a high body mass index; the presence of hypertension”

    Reviewin older people living with HIV

    Risks of Type 2 diabetes among older people living with HIV: A scoping review

    South African family practice : official journal of the South African Academy of Family Practice/Primary Care

More on Type 2 diabetes

Hypertension

upin humans2

2 studies
  1. Antiretroviral therapy is associated with hypertension in persons living with HIV (aRR 1.52, 95% CI 1.22-1.89).

    “hypertension (aRR 1.52, 95% CI 1.22-1.89)”

    Humansin persons living with HIV

    Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

    BMC infectious diseases

  2. Antiretroviral therapy is associated with hypertension in people living with HIV in sub-Saharan Africa (1.23 times greater).

    “1.23 times greater in individuals receiving antiretroviral therapy (ART)”

    Reviewin people living with HIV in sub-Saharan African = 193,843

    Hypertension among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis

    Scientific reports

More on Hypertension

Dyslipidemia

upin humans2+64% overall prevalence

2 studies
  1. Antiretroviral therapy is associated with dyslipidemia in persons living with HIV (aRR 1.35, 95% CI 1.20-1.52).

    “longer ART exposure was associated with dyslipidemia (aRR 1.35, 95% CI 1.20-1.52)”

    Humansin persons living with HIV

    Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

    BMC infectious diseases

  2. Antiretroviral therapy is associated with dyslipidemia in humans (asymptomatic people living with HIV/AIDS) (64% overall prevalence).

    “Our results showed a high prevalence of dyslipidemic individuals (64%), especially in those under ART.”

    Humansasymptomatic people living with HIV/AIDSn = 94

    Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA

    Journal of applied biomedicine

More on Dyslipidemia

Erectile dysfunction

upin humans1OR 1.62

1 study
  1. Antiretroviral therapy is associated with erectile dysfunction in humans (men living with HIV) (OR 1.62, 95% CI 1.27–2.08).

    “Erectile dysfunction is associated with age and with cardiometabolic, psychological, endocrine, and treatment-related factors.”

    Reviewmen living with HIVmales

    Prevalence and Factors Associated with Erectile Dysfunction Among Men Living with HIV: A Systematic Review, Meta-Analysis, and Meta-Regression

    International journal of sexual health : official journal of the World Association for Sexual Health

More on Erectile dysfunction

Body weight

upin humans1

1 study
  1. Antiretroviral therapy is associated with body weight in humans (people with HIV).

    “ART-associated weight gain is heterogeneous rather than a uniform restorative process.”

    Reviewpeople with HIV

    Antiretroviral therapy, adiposity, and cardiometabolic risk in people with HIV

    The lancet. HIV

All 46

Funding

8 grants since 2018

National Institute of Arthritis and Musculoskeletal and Skin Diseases$4.4MNational Institute on Drug Abuse$2.4MNational Institute of Dental and Craniofacial Research$1.9M

Latest

Dec 2025: 6Jan 2026: 4Feb 2026: 9Mar 2026: 6Apr 2026: 9May 2026: 3Jun 2026: 4Jul 2026: 1Aug 2026: 1Sep 2026: 8Oct 2026: 9Nov 2026: 464 papers in 12 months

See all 226 papers on antiretroviral therapy